Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 7.38 USD 5.81%
Market Cap: $578.9m

Replimune Group Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Replimune Group Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Replimune Group Inc
NASDAQ:REPL
Other Items
$102.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$5.9B
CAGR 3-Years
-108%
CAGR 5-Years
31%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$3B
CAGR 3-Years
-22%
CAGR 5-Years
8%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Other Items
-$1.3B
CAGR 3-Years
13%
CAGR 5-Years
33%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$1.1B
CAGR 3-Years
-40%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
$691.2m
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

Replimune Group Inc
Glance View

Market Cap
578.9m USD
Industry
Biotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

REPL Intrinsic Value
HIDDEN
Show

See Also

What is Replimune Group Inc's Other Items?
Other Items
102.2m USD

Based on the financial report for Sep 30, 2025, Replimune Group Inc's Other Items amounts to 102.2m USD.

What is Replimune Group Inc's Other Items growth rate?
Other Items CAGR 1Y
-11%

Over the last year, the Other Items growth was -11%.

Back to Top